Symbols

SPRO

Spero Therapeutics·NASDAQ

--(--)

SPRO Profile

Spero Therapeutics, Inc.

A multi-asset, clinical-stage biopharmaceutical company focused on novel treatments for bacterial infections, including multi-drug resistant bacterial infections and rare diseases

Industry

Pharmaceutical

Established Date

Listing Date

11/02/2017

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.sperotherapeutics.com

Security Type

Common stock

Office address

675 Massachusetts Avenue 14th Floor Cambridge Massachusetts 02139

Business

Introduction

Spero Therapeutics, Inc., was incorporated in December 2013 under the laws of the State of Delaware. The company is a clinical-stage biopharmaceutical company focused on identifying and developing new therapies for rare diseases and diseases with high unmet need. The company's clinical stage product candidate teipenem HBr has completed its second Phase 3 trial and has the potential to be the first oral carbapenem for the treatment of adult patients with complex urinary tract infections caused by certain microorganisms, including pyelonephritis.